<DOC>
	<DOCNO>NCT00224549</DOCNO>
	<brief_summary>The purpose study assess efficacy two different treatment regimen treat resistant hypertension previously uncontrolled least 3 antihypertensive treatment . The study hypothesis two regimen ( one base increase diuretic base increase renin angiotensin system blockage ) may differ term efficacy .</brief_summary>
	<brief_title>PHARES Study : Management Resistant Hypertension</brief_title>
	<detailed_description>Tested hypothesis : For essential resistant hypertension , new regimen base intensive RAS blockage non inferior recommend regimen base intensive sodium depletion . Primary objective : To demonstrate non-inferiority ( i.e difference two regimen less 5 mmHg mean day-time SBP week 12 ) - One treatment arm include irbesartan 300 mg , hydrochlorothiazide ( HCTZ ) 12.5mg , amlodipine 5 mg , ramipril 10mg bisoprolol 10 mg - One treatment arm include irbesartan 300 mg , HCTZ 12.5mg , amlodipine 5 mg , spironolactone 25 mg , furosemide 40 mg amiloride 5 mg . Secondary objective : - To assess clinical biological safety efficacy regimen - To evaluate predicted factor control uncontrolled BP - To evaluate compliance treatment - To compare cost different strategy - To compare two strategy term endothelial function leave ventricular diastolic filling Study design : - Period 1 week-4 week 0 : 4-week treatment patient irbesartan 300 mg , HCTZ 12.5mg , amlodipine 5 mg. At end period , ABPM perform : patient mean day time SBP &gt; 135 and/or DBP &gt; 85 mmHg randomize 3 month treatment - Period 2 week 0 week 4 : patient randomize two group , first one receive spironolactone 25mg second one receive ramipril 5 mg add-on therapy ( top previous tri-therapy ) . - Period 3 week 4 week 8 : Patients BP control week 4 ( i.e mean home blood pressure measurement ( HBPM ) &lt; 135/85 mmHg week 4 ) remain treatment . For uncontrolled ( i.e . mean HBPM &gt; 135/85 mmHg week 4 ) , furosemide 20 mg add first group ramipril titrate 10 mg second group - Period 4 week 8 week 10 : Patients BP control week 8 ( i.e . mean HBPM &lt; 135/85 mmHg week 8 ) remain treatment . For uncontrolled ( i.e . mean HBPM &gt; 135/85 mmHg week 8 ) , furosemide titrate 40 mg first group bisoprolol 5 mg add second group . - Period 5 week 10 week 12 ( end study ) : Patients BP control week 10 ( i.e mean HBPM &lt; 135/85 mmHg week 10 ) remain treatment . For uncontrolled ( i.e mean HBPM &gt; 135/85 mmHg week 10 ) , amiloride 5 mg add previous treatment first group bisoprolol titrate 10 mg second group . Reasons treatment discontinuation : - Patient decision - Informed consent withdrawal - SBP &gt; 180 mmHg &lt; 100 mmHg ( HBPM ) whatever time trial - Adverse event related treatment</detailed_description>
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<mesh_term>Hydrochlorothiazide</mesh_term>
	<mesh_term>Amlodipine</mesh_term>
	<criteria>Primary hypertension Resistant hypertension define mean daytime SBP &gt; 135 mmHg DBP &gt; 85 mmHg ( determine ABPM device ) standardize 4week regimen include irbesartan , amlodipine HCTZ . Secondary hypertension Unstable angina , history stroke coronary heart disease ( coronary bypass angioplasty ) previous 3 month History cough ACEi gynecomastia antialdosterones Heart failure ( New York Heart Association [ NYHA ] IIIIV ) Contraindication beta blocker bronchopathy auriculoventricular block Diabetes mellitus ( type 1 2 ) HbA1C &gt; 8 % Renal failure creatinine clearance &lt; 40ml/min ( COCKROFT evaluation ) Arm circumference &gt; 42 cm</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2007</verification_date>
	<keyword>Resistant hypertension</keyword>
	<keyword>Combined diuretic therapy</keyword>
	<keyword>Combined RAS blocker</keyword>
</DOC>